Voon, V
Derbyshire, K
Rück, C
Irvine, M A
Worbe, Y
Enander, J
Schreiber, L R N
Gillan, C
Fineberg, N A
Sahakian, B J
Robbins, T W
Harrison, N A
Wood, J
Daw, N D
Dayan, P
Grant, J E
Bullmore, E T
Article History
Received: 28 October 2013
Revised: 24 February 2014
Accepted: 17 March 2014
First Online: 20 May 2014
Competing interests
: ETB is employed part-time by the University of Cambridge and part-time by GSK PLC and is a shareholder of GSK. TWR is a consultant for Cambridge Cognition, Eli Lilly, GSK, Merck, Sharpe and Dohme, Lundbeck, Teva and Shire Pharmaceuticals. He is or has been in receipt of research grants from Lundbeck, Eli Lilly and GSK and is an editor for Springer-Verlag (Psychopharmacology). JWD is a consultant for Boehringer Ingelheim and has received grants from this company. JEG has received research grant support from NIDA, NCRG, Psyadon Pharmaceuticals and Transcept Pharmaceuticals. He has also received royalties from American Psychiatric PublishingA, Oxford University Press, Norton, and McGraw Hill Publishers. The remaining authors report no conflicts of interest.